Post on 29-Jun-2015
description
transcript
Ivan M. AfanasoveFtek-BIO llc managing director
ef-tek.ru
EXPRESS ONCOTEST
SKOLKOVO, 05/27/2013
EFTEK-BIO LLC
2Express Oncotest
Express test microstructure
•In Russia, only 10% of of breast cancer cases are diagnosed at early stages
•only 57% women survive at least for 5 years after cancer diagnosis
•27 million women (>40 years) require annual breast screening
•It is impossible to screen such a large number of patients instrumentally and in laboratory
•Biopolymeric nanofibers
•Immobilized antibodies
•Contact of biological material with
the substrate
•Simple visualisation of the
antibody-antigene interaction
EXPRESS ONCOTESTHOME-USE TESTFOR EARLY STAGE CANCER
DIAGNOSTICS NEEDED
Problem & Solution
Market Team Action Plan
3
•The market is growing, amounting globally $ 6,4 BLN in 2020•% of elder people is steadily increasing and will reach 37% by 2050 in Russia
2013 2014 2015 2016 2017 2018 2019 2020
4.24 4.52
4.81 5.11
5.42 5.74
6.07 6.41
Global Market Volume, $ bln
Express Oncotest
Market
Team Action Plan
Problem & Solution
4
•All existing diagnostics is either instrumental (as mammography) or laboratory (requires blood analysis)•No express personal tests available
• Prompt diagnosis without laboratory equipment• Supplies as a part of National programmes for
women’s health
b2bHealth
Facilities
• Oncotest – good alternative for a mammologist consultation
• Supply to national distribution companies
b2cWomen
>40 years
Market
Team Action Plan
Problem & Solution
Breast Cancer Diagnostics
ClinicalEarly (initial)
Instrumental
LaboratoryAt home
Express Oncotest
5
Technology Business
•PhD, 17 papers, 16 patents• CEO, Eftek llc• winner of the contests for the scholarships of the President of Russia and the Academic Council of Lomonosov Moscow State University
• PhD, 192 papers• 34 years of experience in
R&D of novel functional materials• Professor at N.Semenov
Institute of chemical Physics
• PhD, 172 papers, 12 patents• 6 years experience in
electrospinning• 20 years experience in
R&D of biopolymers and biologically active molecules
• PhD, 70 papers, 9 patents•Associate Professor in
the First MGMU•Assistant rector of
RGMU after Pirogov for Science and Innovation
Medicine
Problem & Solution
MarketTeam
Action Plan
Ivan M. Afanasov, Project leader
Alexey L. IordanskiiAnalysis of structure and
properties of substrate with immobilized antibodies
Tatyana N. YudanovaSubstrate development,
immobilization of bioactive molecules
Vladislav Y. ZhemchugovBiomedical tests
Express Oncotest
6
Problem & Solution
Market Team
Action Plan
• The team• R&D and Marketing Plan• Research & Production
Facilities
• Proof-of-concept• Prototype
• R&D: qualitative analysis,
increase of sensitivity, specificity and stability
• Product registration• Ru & PCT application• Marketing
• Marketing• Pilot batch
production
COMPLETED
$ 170 000 II.2013-II.2014
$ 740 000 II.2014-II.2015
$ 440 000Sales start in III.2015
Express Oncotest
7Express Oncotest
R&D plan
Investment planCompetitor’s analysis
Project history
Business strategy
Thank you!
Questions?
Ivan M. AfanasovEFTEK-BIO LLC managing director
ivan.afanasov@gmail.comef-tek.ru
8Express Oncotest
Substrate development*
• Contains >50% nanoribbons
Immobilization of antibodies in/onto
a nanofibrous substrate
Experimental proof of the
Oncotest mechanism
Prototype
R&D Plan SEED Stage
9Express Oncotest
Action plan Completed Seed stage 1st stage
Timeline IV, 2012 I, 2013 II, 2013 III, 2013 IV, 2013 I, 2014 II,
2014III,
2014IV,
2014 I, 2015 II, 2015
R&D 1. Development of electrospinning technology of chitosan nonorfibers containing >10% nanoribbons ˅ ˅
2. Development of electrospinning technology of chitosan nonorfibers containing >50% nanoribbons ˅ ˅ ˅
3. Development of a technology of Immobilization of antibodies in/onto a nanofibrous substrate ˅ ˅
4. Comparatative characteristics of detection of tumor markers in spittle& blood (spped, sensitivity, specificity) - literature review and development
˅ ˅
5. Experimental proof of the Oncotest mechanism ˅ ˅ ˅ a) Visualsation adaptation ˅
b) Qualitative detection of tumor markers ˅ ˅ ˅c) Preclinical tests on biological models ˅ ˅ 6.Prototype launch and technical deocumentation project development ˅
Marketing 1. Market analysis ˅ 2. Communications with potential customers ˅ IP 1. Patent search ˅ 2. Рknow how registration ˅ 3. RU application ˅ 4. PCT application ˅ Finance 1. Skolkovo grant ˅ 2. Venture finance/1st stage grant ˅
10Express Oncotest
Competitor’s analysis Breast Cancer Diagnostics
ClinicalEarly (initial)
Instrumental LaboratoryAt home
Product Stage Sensitivity SampleEase of use
Price, rub.
BrEp-test / ИХБФМ СО РАН
under development
90% Blood No 800
CanAg / Fujirebio, Sweden
on market < 1 U/mL Blood No12 000 – 24 per set (1 200 – 2 000 per 1 analysis)
PF-Biochip (РМЖ) / «Biochip-imb» llc
on market20 ng DNA in a ssample
Blood/ spittle
No ̴�of a PCR analysis
ONCOTEST / eFtek-Bio llc
under development
to be determined
Blood/ spittle/urine
YES < 800
• > 250 mln screenings annually
• Market volume $ 6,4 BLN
palpation, onco-epidemological test
ONCOTEST
radiothermometry, electrical impedance tomography, mammography,ultrasound
tumor markersRNA and DNA diagnostics
11Express Oncotest
Business Strategy
2013 - Consultations with doctors
2014-15 - Exhibitions and conferences
2015-16 – Product launch under the brand of a major
pharmacy chain + Regional dealer agreements to supply to
health facilities
2016 – Supply to national distribution companies for
pharmacy chains• Prompt diagnosis without laboratory equipment• Supplies as a part of National programmes for
women’s health
b2bHealth
Facilities
• Oncotest – good alternative for a mammologist consultation
• Supply to national distribution companies
b2cWomen
>40 years